Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ.
Authors:
Journal: Nature communications
Publication Type: Journal Article
Date: 2017
DOI: PMC5643371
ID: 29038423
Abstract
Phosphatidylinositol-3-kinases (PI3K) γ and δ are preferentially enriched in leukocytes, and defects in these signaling pathways have been shown to impair T cell activation. The effects of PI3Kγ and PI3Kδ on alloimmunity remain underexplored. Here, we show that both PI3Kγ and PI3Kδ mice receiving heart allografts have suppression of alloreactive T effector cells and delayed acute rejection. However, PI3Kδ mutation also dampens regulatory T cells (Treg). After treatment with low dose CTLA4-Ig, PI3Kγ , but not PI3Κδ , recipients exhibit indefinite prolongation of heart allograft survival. PI3Kδ Tregs have increased apoptosis and impaired survival. Selective inhibition of PI3Kγ and PI3Kδ (using PI3Kδ and dual PI3Kγδ chemical inhibitors) shows that PI3Kγ inhibition compensates for the negative effect of PI3Kδ inhibition on long-term allograft survival. These data serve as a basis for future PI3K-based immune therapies for transplantation.Phosphatidylinositol-3-kinases (PI3K) γ and δ are key regulators of T cell signaling. Here the author show, using mouse heart allograft transplantation models, that PI3Kγ or PI3Kδ deficiency prolongs graft survival, but selective inhibition of PI3Kγ or PI3Kδ reveals alternative transplant survival outcomes post CTLA4-Ig treatment.
Chemical List
- Immunosuppressive Agents|||Abatacept|||Class I Phosphatidylinositol 3-Kinases|||Class Ib Phosphatidylinositol 3-Kinase|||Pik3cd protein, mouse|||Pik3cg protein, mouse
Reference List
- Kobashigawa JA. The future of heart transplantation. Am. J. Transplant. 2012;12:2875–2891. doi: 10.1111/j.1600-6143.2012.04223.x.|||Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N. Eng. J. Med. 2010;363:1451–1462. doi: 10.1056/NEJMra0902927.|||Kobashigawa JA, Patel JK. Immunosuppression for heart transplantation: where are we now? Nat. Clin. Pract. Cardiovasc. Med. 2006;3:203–212. doi: 10.1038/ncpcardio0510.|||Walker EH, Perisic O, Ried C, Stephens L, Williams RL. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature. 1999;402:313–320. doi: 10.1038/46319.|||Ruckle T, Schwarz MK, Rommel C. PI3Kgamma inhibition: towards an ‘aspirin of the 21st century’? Nat. Rev. Drug Discov. 2006;5:903–918. doi: 10.1038/nrd2145.|||Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 2005;30:194–204. doi: 10.1016/j.tibs.2005.02.008.|||Fruman DA, Cantley LC. Phosphoinositide 3-kinase in immunological systems. Semin. Immunol. 2002;14:7–18. doi: 10.1006/smim.2001.0337.|||Rommel C, Camps M, Ji H. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 2007;7:191–201. doi: 10.1038/nri2036.|||Vanhaesebroeck B, Vogt PK, Rommel C. PI3K: from the bench to the clinic and back. Curr. Top. Microbiol. Immunol. 2010;347:1–19.|||Williams O, et al. Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs. Chem. Biol. 2010;17:123–134. doi: 10.1016/j.chembiol.2010.01.010.|||Hawkins PT, Stephens LR. PI3K signalling in inflammation. Biochim. Biophys. Acta. 2015;1851:882–897. doi: 10.1016/j.bbalip.2014.12.006.|||Barber DF, et al. Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion. J. Immunol. 2006;176:589–593. doi: 10.4049/jimmunol.176.1.589.|||Barbi J, et al. PI3Kgamma (PI3Kgamma) is essential for efficient induction of CXCR3 on activated T cells. Blood. 2008;112:3048–3051. doi: 10.1182/blood-2008-02-135715.|||Alcazar I, et al. Phosphoinositide 3-kinase gamma participates in T cell receptor-induced T cell activation. J. Exp. Med. 2007;204:2977–2987. doi: 10.1084/jem.20070366.|||Azzi J, et al. The novel therapeutic effect of phosphoinositide 3-kinase-gamma inhibitor AS605240 in autoimmune diabetes. Diabetes. 2012;61:1509–1518. doi: 10.2337/db11-0134.|||Okkenhaug K, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science. 2002;297:1031–1034.|||Okkenhaug K, et al. The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J. Immunol. 2006;177:5122–5128. doi: 10.4049/jimmunol.177.8.5122.|||Rolf J, et al. Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction. J. Immunol. 2010;185:4042–4052. doi: 10.4049/jimmunol.1001730.|||Soond DR, et al. PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood. 2010;115:2203–2213. doi: 10.1182/blood-2009-07-232330.|||Macintyre AN, et al. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity. 2011;34:224–236. doi: 10.1016/j.immuni.2011.01.012.|||Han JM, Patterson SJ, Levings MK. The role of the PI3K signaling pathway in CD4(+) T cell differentiation and function. Front Immunol. 2012;3:245.|||Sauer S, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl Acad. Sci. USA. 2008;105:7797–7802. doi: 10.1073/pnas.0800928105.|||Patton DT, et al. Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+regulatory T cells. J. Immunol. 2006;177:6598–6602. doi: 10.4049/jimmunol.177.10.6598.|||Patton DT, Wilson MD, Rowan WC, Soond DR, Okkenhaug K. The PI3K p110delta regulates expression of CD38 on regulatory T cells. PLoS ONE. 2011;6:e17359. doi: 10.1371/journal.pone.0017359.|||Birnbaum LM, et al. Management of chronic allograft nephropathy: a systematic review. Clin. J. Am. Soc. Nephrol.: 2009;4:860–865. doi: 10.2215/CJN.05271008.|||Colvin RB. Chronic allograft nephropathy. N. Eng. J. Med. 2003;349:2288–2290. doi: 10.1056/NEJMp038178.|||Floess S, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007;5:e38. doi: 10.1371/journal.pbio.0050038.|||Kim HP, Leonard WJ. CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J. Exp. Med. 2007;204:1543–1551. doi: 10.1084/jem.20070109.|||Bartok B, et al. PI3 kinase delta is a key regulator of synoviocyte function in rheumatoid arthritis. Am. J. Pathol. 2012;180:1906–1916. doi: 10.1016/j.ajpath.2012.01.030.|||Cornell LD, Smith RN, Colvin RB. Kidney transplantation: mechanisms of rejection and acceptance. Annu. Rev. Pathol. 2008;3:189–220. doi: 10.1146/annurev.pathmechdis.3.121806.151508.|||Le Moine A, Goldman M, Abramowicz D. Multiple pathways to allograft rejection. Transplantation. 2002;73:1373–1381. doi: 10.1097/00007890-200205150-00001.|||Land W. Innate alloimmunity: history and current knowledge. Exp. Clin. Transplant. 2007;5:575–584.|||Chen L, et al. TLR engagement prevents transplantation tolerance. Am. J. Transplant. 2006;6:2282–2291. doi: 10.1111/j.1600-6143.2006.01489.x.|||Wang T, et al. Prevention of allograft tolerance by bacterial infection with Listeria monocytogenes. J. Immunol. 2008;180:5991–5999. doi: 10.4049/jimmunol.180.9.5991.|||Liu G, Wu Y, Gong S, Zhao Y. Toll-like receptors and graft rejection. Transpl. Immunol. 2006;16:25–31. doi: 10.1016/j.trim.2006.03.006.|||Gorbacheva V, Fan R, Li X, Valujskikh A. Interleukin-17 promotes early allograft inflammation. Am. J. Pathol. 2010;177:1265–1273. doi: 10.2353/ajpath.2010.091106.|||Yuan X, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J. Exp. Med. 2008;205:3133–3144. doi: 10.1084/jem.20081937.|||Ali K, et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014;510:407–411.|||Polansky JK, et al. DNA methylation controls Foxp3 gene expression. Eur. J. Immunol. 2008;38:1654–1663. doi: 10.1002/eji.200838105.|||Soond DR, Slack EC, Garden OA, Patton DT, Okkenhaug K. Does the PI3K pathway promote or antagonize regulatory T cell development and function? Front. Immunol. 2012;3:244. doi: 10.3389/fimmu.2012.00244.|||Brown JR, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–3397. doi: 10.1182/blood-2013-11-535047.|||Hedrick SM, Hess Michelini R, Doedens AL, Goldrath AW, Stone EL. FOXO transcription factors throughout T cell biology. Nat. Rev. Immunol. 2012;12:649–661. doi: 10.1038/nri3278.|||Kim EH, Suresh M. Role of PI3K/Akt signaling in memory CD8 T cell differentiation. Front. Immunol. 2013;4:20.|||Crellin NK, Garcia RV, Levings MK. Altered activation of AKT is required for the suppressive function of human CD4+CD25+T regulatory cells. Blood. 2007;109:2014–2022. doi: 10.1182/blood-2006-07-035279.|||Finlay DK. Regulation of glucose metabolism in T cells: new insight into the role of Phosphoinositide 3-kinases. Front. Immunol. 2012;3:247.|||King CG, et al. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat. Med. 2006;12:1088–1092. doi: 10.1038/nm1449.|||Ben Ahmed M, et al. IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway. J. Immunol. 2009;182:6763–6770. doi: 10.4049/jimmunol.0801792.|||Huynh A, et al. Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat. Immunol. 2015;16:188–196. doi: 10.1038/ni.3077.|||De Henau O, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature. 2016;539:443–447. doi: 10.1038/nature20554.|||Kaneda MM, et al. PI3Kgamma is a molecular switch that controls immune suppression. Nature. 2016;539:437–442. doi: 10.1038/nature19834.|||Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation. 2012;93:1–10. doi: 10.1097/TP.0b013e31823cab44.|||Banham-Hall E, Clatworthy MR, Okkenhaug K. The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol. J. 2012;6:245–258. doi: 10.2174/1874312901206010245.|||Barber DF, et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 2005;11:933–935.|||Camps M, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 2005;11:936–943.|||Lezama-Davila CM, et al. Role of phosphatidylinositol-3-kinase-gamma (PI3Kgamma)-mediated pathway in 17beta-estradiol-induced killing of L. mexicana in macrophages from C57BL/6 mice. Immunol. Cell Biol. 2008;86:539–543. doi: 10.1038/icb.2008.39.|||Eickholt BJ, et al. Control of axonal growth and regeneration of sensory neurons by the p110delta PI 3-kinase. PLoS ONE. 2007;2:e869. doi: 10.1371/journal.pone.0000869.|||Corry RJ, Winn HJ, Russell PS. Heart transplantation in congenic strains of mice. Transplant. Proc. 1973;5:733–735.|||Billingham ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group. The international society for heart transplantation. J. Heart Transplant. 1990;9:587–593.|||Stewart S, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transplant. 2005;24:1710–1720. doi: 10.1016/j.healun.2005.03.019.|||Jurewicz M, et al. Donor antioxidant strategy prolongs cardiac allograft survival by attenuating tissue dendritic cell immunogenicity(dagger) Am. J. Transplant. 2011;11:348–355. doi: 10.1111/j.1600-6143.2010.03360.x.|||Winkler DG, et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem. Biol. 2013;20:1364–1374. doi: 10.1016/j.chembiol.2013.09.017.